Enzo Biochem (ENZ) Azione Prezzo
Enzo Biochem Prezzo
Negli ultimi 19 anni Enzo Biochem ha aumentato il fatturato del 18,4% all'anno, raggiungendo 992,90 Mio. USD. L'utile per azione è diminuito del 30,0% all'anno negli ultimi 5 anni. Per Enzo Biochem, il margine netto del -0,8% risulta in calo rispetto al 6,7% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 18,20%.
Enzo Biochem Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Enzo Biochem Azione e analisi azionaria
Domande frequenti sull'azione Enzo Biochem
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.
The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.
Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.
Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.
Enzo Biochem Inc is primarily present in the United States.
Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.
5 analisti valutano attualmente l’azione Enzo Biochem: 4 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Enzo Biochem ricavi pari a 107,03 Mio. USD e un utile per azione di -0,07 USD.
Convertita al tasso di cambio attuale, l’azione Enzo Biochem quota 0,49 EUR (0,55 USD).
L’azione Enzo Biochem (ENZ) è quotata su 6 borse, tra cui: NYSE (ENZ), London (0IHV.L), SIX (Zürich) (EZB.SW), Frankfurt (EZB.F), München (EZB.MU), Düsseldorf (EZB.DU).
Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.
Il attesa fatturato di Enzo Biochem ammonta a 107,03 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Enzo Biochem ammonta a -9,72 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Enzo Biochem è attualmente -7,85. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Enzo Biochem.
Il rapporto prezzo/fatturato (P/S) di Enzo Biochem è attualmente 0,71. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Enzo Biochem.
Il Quality Score AlleAktien per Enzo Biochem è 5/10.
L'ISIN di Enzo Biochem è US2941001024. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Enzo Biochem è 865607. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Enzo Biochem è ENZ. Con questo simbolo di borsa vengono negoziate le azioni Enzo Biochem in borsa.
Azione Enzo Biochem
Gruppo di pari di Enzo Biochem
Enzo Biochem Ticker
Enzo Biochem FIGI
Altre metriche e analisi di Enzo Biochem in Deep Dive.
La nostra analisi azionaria dell'azione Enzo Biochem include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Enzo Biochem. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: